This database contains 7 studies, archived under the term: "Apolipoprotein"
The effects of ramipril in individuals at risk for Alzheimer’s disease: results of a pilot clinical trial
Wharton, Whitney,
Stein, James H.,
Korcarz, Claudia,
Sachs, Jane,
Olson, Sandra R.,
Zetterberg, Henrik,
Dowling, Maritza,
Ye, Shuyun,
Gleason, Carey E.,
Underbakke, Gail,
Jacobson, Laura E.,
Johnson, Sterling C.,
Sager, Mark A.,
Asthana, Sanjay,
Carlsson, Cynthia M.
Research shows that certain antihypertensives taken during midlife confer Alzheimer’s disease (AD) related benefits in later life. We conducted a clinical trial to evaluate the extent to which the angiotensin converting enzyme inhibitor (ACE-I), ramipril, affects AD biomarkers including cerebrospinal fluid (CSF) amyloid-β (Aβ) levels and ACE activity, arterial function, and cognition in participants with […]
Response to rivastigmine transdermal patch or memantine plus rivastigmine patch is affected by apolipoprotein E genotype in Alzheimer patients
Han, Hyun Jeong,
Kim, Byeong C.,
Lee, Jun-Young,
Ryu, Seung-Ho,
Na, Hae-Ri,
Yoon, Soo Jin,
Park, Hyun Young,
Shin, Joon Hyun,
Cho, Soo-Jin,
Yi, Hyon Ah,
Choi, Mun Seong,
Heo, Jae-Hyeok,
Park, Kyung Won,
Kim, Kwang K.,
Choi, Seong Hye
Background/aims: The apolipoprotein E (APOE) genotype in response to pharmacological treatments in patients with Alzheimer’s disease (AD) remains a matter of controversy. This analysis investigated the effect of the APOE genotype on the clinical response to rivastigmine transdermal patch monotherapy or memantine plus rivastigmine patch in patients with mild to moderate AD.; Methods: Two hundred […]
Disclosure of APOE genotype for risk of Alzheimer’s disease
Green, Robert C.,
Roberts, J. Scott,
Cupples, L. Adrienne,
Relkin, Norman R.,
Whitehouse, Peter J.,
Brown, Tamsen,
Eckert, Susan LaRusse,
Butson, Melissa,
Sadovnick, A. Dessa,
Quaid, Kimberly A.,
Chen, Clara,
Cook-Deegan, Robert,
Farrer, Lindsay A.
Background: The apolipoprotein E (APOE) genotype provides information on the risk of Alzheimer’s disease, but the genotyping of patients and their family members has been discouraged. We examined the effect of genotype disclosure in a prospective, randomized, controlled trial.; Methods: We randomly assigned 162 asymptomatic adults who had a parent with Alzheimer’s disease to receive […]
Rosiglitazone monotherapy in mild-to-moderate Alzheimer’s disease: results from a randomized, double-blind, placebo-controlled phase III study
Gold, Michael,
Alderton, Claire,
Zvartau-Hind, Marina,
Egginton, Sally,
Saunders, Ann M.,
Irizarry, Michael,
Craft, Suzanne,
Landreth, Gary,
Linnamägi, Ulla,
Sawchak, Sharon
Background/aims: A phase II study of the peroxisome proliferator-activated receptor-γ agonist rosiglitazone extended release (RSG XR) in mild-to-moderate Alzheimer’s disease (AD) detected a treatment benefit to cognition in apolipoprotein E(APOE)-ε4-negative subjects. The current phase III study with prospective stratification by APOE genotype was conducted to confirm the efficacy and safety of RSG XR in mild-to-moderate […]
Neuroimaging predictors of brain amyloidosis in mild cognitive impairment
Objective: To identify a neuroimaging signature predictive of brain amyloidosis as a screening tool to identify individuals with mild cognitive impairment (MCI) that are most likely to have high levels of brain amyloidosis or to be amyloid-free.; Methods: The prediction model cohort included 62 MCI subjects screened with structural magnetic resonance imaging (MRI) and (11) […]